目的 研究华蟾素注射液辅助治疗前列腺癌的临床疗效。方法 收集2015年1月—2017年2月襄阳市中心医院（湖北文理学院附属医院）肿瘤科收治的前列腺癌患者110例，随机分为对照组和治疗组，每组各55例。对照组患者给予相应的放化疗治疗。治疗组在放化疗开始时即静脉滴注华蟾素注射液，10～20 mL稀释于5%葡萄糖注射液250 mL中，连续用药6 d，停药1 d。连续用药3周为1个疗程，共治疗4个疗程。观察两组的临床疗效，比较两组治疗前后血清前列腺特异抗原（PSA）水平和毒副反应。结果 治疗后，对照组客观缓解率（ORR）是69.09%，临床获益率（CBR）是85.45%；治疗组ORR是89.09%，CBR是96.36%，两组ORR、CBR比较差异有统计学意义（P<0.05）。治疗后，两组患者血清PSA水平均显著降低，同组治疗前后差异有统计学意义（P<0.05）；治疗后，治疗组血清PSA水平显著低于对照组，两组比较差异有统计学意义（P<0.05）。治疗组患者白细胞减少、恶心呕吐的发生率明显低于对照组，两组比较差异有统计学意义（P<0.05）。结论 华蟾素注射液辅助治疗前列腺癌临床疗效确切，能显著降低血清PSA水平，减少患者白细胞降低和恶心呕吐的发生率，具有一定的临床推广应用价值。

Objective To investigate the efficacy of Cinobufacin Injection in treatment of prostate cancer. Methods Patients (110 cases) with prostate cancer in Oncology Department of Xiangyang Central Hospital (the Affiliated Hospital of Hubei University of Arts and Science) from January 2015 to February 2017 were randomly divided into control (55 cases) and treatment (55 cases) groups. Patients in the control group were treated with radiotherapy and chemotherapy. Patients in the treatment group were iv administered with Cinobufacin Injection, 10-20 mL was diluted in 5% glucose injection 250 mL, continuous treatment for 6 d, stop 1 d. Three weeks were 1 course of treatment and they were treated for 4 courses. After treatment, the clinical efficacy was evaluated, and the serum prostate specific antigen (PSA) level and the toxic side reaction in two groups were compared. Results After treatment, the ORR and CBR in the control group were 69.09% and 85.45%, and the ORR and CBR in the treatment group were 89.09% and 96.36%, and there were differences between two groups (P < 0.05). After treatment, PSA in two groups were significantly decreased, and there were differences in the same group (P < 0.05). After treatment, PSA in the treatment group was lower than that in the control group, and there were differences between two groups (P < 0.05). The leukocyte reduction incidence, and nausea and vomiting incidence in the treatment group was significantly lower than those in the control group, and there were differences between two groups (P < 0.05). Conclusion Cinobufacin Injection has significant clinical effect in treatment of prostate cancer, and can significantly reduce the serum PSA level, and also can reduce the incidence of leukocyte reduction and nausea and vomiting, which has a certain clinical application value.